Santhera estimates the peak product sales potential for vamorolone in the indication DMD alone to be in excess of US-$500m in the US and the largest five European countries combined. Vamorolone binds to the same receptor as corticosteroids but modifies its downstream activity and as such is a dissociative agonist. This mechanism has the potential to 'dissociate' efficacy from typical steroid safety concerns and therefore vamorolone could emerge as a promising alternative to existing corticosteroids, the current standard of care in children and adolescents with DMD. In the pivotal VISION-DMD study, compared to prednisone, vamorolone showed comparable efficacy, improvements on multiple safety parameters and was associated with fewer adverse events.